Pain Management · 2020 · 28 citations · 18 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyDrug DeliveryPain MedicineHeadache DisordersHeadache ManagementMicroneedle-based DeliveryMigraine PharmacotherapyPharmacologic Pain TherapyAcute Headache ManagementAcute Migraine TreatmentMicroneedlesMigraine PharmacologyPost Hoc Analysis
M207 is an investigational intracutaneous microneedle therapeutic system for nonoral zolmitriptan delivery. In a Phase I trial, M207 provided faster absorption with a higher 2 h exposure than oral zolmitriptan. In the pivotal trial evaluating efficacy, tolerability and safety in moderate-to-severe migraine attacks, M207 3.8 mg was superior to placebo in providing freedom from headache pain (42 vs 14%) and freedom from most bothersome symptom (68 vs 43%) 2 h post-dose. Treatment-emergent adverse events were mild and transient and most commonly concerned the application site. In post hoc analyses: pain freedom was sustained in approximately 1/3 of patients; efficacy was observed in migraine headaches that are typically more difficult to treat.
18
Peter E. Daddona, James A. Matriano, Jaap W. Mandema et al. · Pharmaceutical Research · 2010 · 232 citations
Treatment of acute migraine headache.
Benjamin Gilmore, Magdalena Michael · PubMed · 2011 · 140 citations
Eletriptan in the Early Treatment of Acute Migraine: Influence of Pain Intensity and Time of Dosing
JL Brandes, David Kudrow, Roger Cady et al. · Cephalalgia · 2005 · 108 citations